Robert Wolfe
Concepts (643)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Muscle Proteins | 88 | 2023 | 303 | 14.510 |
Why?
| Muscle, Skeletal | 110 | 2024 | 750 | 13.720 |
Why?
| Dietary Proteins | 48 | 2024 | 242 | 13.340 |
Why?
| Amino Acids, Essential | 47 | 2024 | 131 | 10.330 |
Why?
| Amino Acids | 60 | 2023 | 360 | 9.310 |
Why?
| Protein Biosynthesis | 28 | 2021 | 253 | 5.340 |
Why?
| Dietary Supplements | 33 | 2024 | 443 | 4.540 |
Why?
| Burns | 28 | 2022 | 162 | 4.320 |
Why?
| Nutritional Requirements | 16 | 2021 | 66 | 3.900 |
Why?
| Aging | 27 | 2020 | 687 | 3.520 |
Why?
| Phenylalanine | 49 | 2022 | 128 | 3.480 |
Why?
| Diet | 15 | 2024 | 566 | 3.470 |
Why?
| Exercise | 28 | 2021 | 495 | 3.450 |
Why?
| Triglycerides | 18 | 2020 | 159 | 3.420 |
Why?
| Sarcopenia | 10 | 2022 | 84 | 3.160 |
Why?
| Proteins | 15 | 2022 | 342 | 3.100 |
Why?
| Milk Proteins | 10 | 2016 | 78 | 3.090 |
Why?
| Isotopes | 6 | 2022 | 23 | 3.040 |
Why?
| Insulin | 39 | 2024 | 457 | 2.800 |
Why?
| Glucose | 18 | 2022 | 344 | 2.660 |
Why?
| Insulin Resistance | 19 | 2024 | 264 | 2.590 |
Why?
| Meals | 12 | 2022 | 57 | 2.560 |
Why?
| Humans | 211 | 2024 | 49974 | 2.260 |
Why?
| Bed Rest | 15 | 2020 | 36 | 2.210 |
Why?
| Leucine | 14 | 2023 | 116 | 2.210 |
Why?
| Body Composition | 27 | 2022 | 318 | 2.160 |
Why?
| Anabolic Agents | 7 | 2019 | 33 | 2.130 |
Why?
| Digestion | 5 | 2020 | 52 | 2.060 |
Why?
| Kinetics | 31 | 2022 | 623 | 2.030 |
Why?
| Liver | 12 | 2021 | 1115 | 2.020 |
Why?
| Energy Intake | 10 | 2024 | 170 | 1.970 |
Why?
| Blood Glucose | 30 | 2020 | 439 | 1.910 |
Why?
| Male | 143 | 2024 | 25241 | 1.900 |
Why?
| Skin | 10 | 2015 | 409 | 1.830 |
Why?
| Aged | 65 | 2024 | 9310 | 1.760 |
Why?
| Weight Loss | 6 | 2018 | 237 | 1.670 |
Why?
| Resistance Training | 11 | 2024 | 92 | 1.660 |
Why?
| Obesity | 14 | 2024 | 1113 | 1.590 |
Why?
| Nutrition Policy | 7 | 2012 | 43 | 1.580 |
Why?
| Rabbits | 22 | 2015 | 370 | 1.570 |
Why?
| Energy Metabolism | 18 | 2019 | 282 | 1.550 |
Why?
| Palmitates | 7 | 2022 | 29 | 1.530 |
Why?
| Feeding Behavior | 7 | 2020 | 181 | 1.520 |
Why?
| Female | 110 | 2024 | 26472 | 1.440 |
Why?
| Muscle Strength | 13 | 2024 | 124 | 1.420 |
Why?
| Animals | 53 | 2024 | 13187 | 1.400 |
Why?
| Carbon Isotopes | 22 | 2017 | 68 | 1.390 |
Why?
| Lipid Metabolism | 7 | 2020 | 175 | 1.380 |
Why?
| Leg | 21 | 2011 | 122 | 1.360 |
Why?
| Arginine | 9 | 2022 | 179 | 1.360 |
Why?
| Hyperinsulinism | 6 | 2015 | 26 | 1.340 |
Why?
| Adult | 77 | 2024 | 13236 | 1.330 |
Why?
| Wound Healing | 6 | 2008 | 204 | 1.290 |
Why?
| Postprandial Period | 10 | 2021 | 69 | 1.290 |
Why?
| Double-Blind Method | 17 | 2021 | 681 | 1.260 |
Why?
| Fatty Acids, Nonesterified | 10 | 2020 | 38 | 1.240 |
Why?
| Heart Failure | 3 | 2019 | 458 | 1.210 |
Why?
| Wounds and Injuries | 6 | 2008 | 276 | 1.120 |
Why?
| Food, Formulated | 4 | 2019 | 42 | 1.080 |
Why?
| Hypoglycemic Agents | 7 | 2013 | 168 | 1.070 |
Why?
| Models, Biological | 12 | 2018 | 727 | 1.050 |
Why?
| Dietary Carbohydrates | 10 | 2021 | 88 | 1.030 |
Why?
| Middle Aged | 58 | 2021 | 12069 | 1.020 |
Why?
| Valerates | 3 | 2017 | 34 | 1.000 |
Why?
| Critical Illness | 8 | 2016 | 288 | 0.990 |
Why?
| Isotope Labeling | 4 | 2019 | 53 | 0.980 |
Why?
| Cross-Over Studies | 13 | 2022 | 224 | 0.910 |
Why?
| Swine | 8 | 2019 | 393 | 0.900 |
Why?
| Overweight | 4 | 2018 | 219 | 0.900 |
Why?
| Pyruvic Acid | 3 | 2021 | 22 | 0.860 |
Why?
| Amino Acids, Branched-Chain | 3 | 2017 | 38 | 0.850 |
Why?
| Hyperglycemia | 6 | 2020 | 79 | 0.830 |
Why?
| Mitochondria, Muscle | 6 | 2024 | 37 | 0.820 |
Why?
| Geriatric Assessment | 2 | 2021 | 112 | 0.810 |
Why?
| Nitric Oxide | 4 | 2015 | 253 | 0.800 |
Why?
| Whole Body Imaging | 2 | 2019 | 22 | 0.780 |
Why?
| Kidney | 2 | 2021 | 665 | 0.780 |
Why?
| Food Analysis | 1 | 2021 | 32 | 0.770 |
Why?
| Deuterium | 11 | 2019 | 42 | 0.760 |
Why?
| Gluconeogenesis | 1 | 2020 | 4 | 0.760 |
Why?
| Lipoproteins, VLDL | 4 | 2024 | 9 | 0.750 |
Why?
| Lactic Acid | 2 | 2021 | 76 | 0.750 |
Why?
| Actinidia | 1 | 2020 | 7 | 0.740 |
Why?
| Glycolysis | 1 | 2021 | 70 | 0.730 |
Why?
| Hydrocortisone | 8 | 2020 | 107 | 0.730 |
Why?
| Muscular Atrophy | 4 | 2021 | 70 | 0.710 |
Why?
| Aged, 80 and over | 13 | 2021 | 3129 | 0.710 |
Why?
| Food, Fortified | 2 | 2021 | 32 | 0.700 |
Why?
| Muscle Contraction | 5 | 2019 | 105 | 0.690 |
Why?
| Caloric Restriction | 3 | 2020 | 36 | 0.690 |
Why?
| Renal Dialysis | 9 | 2015 | 169 | 0.690 |
Why?
| Metformin | 3 | 2005 | 64 | 0.670 |
Why?
| Elder Nutritional Physiological Phenomena | 2 | 2015 | 7 | 0.660 |
Why?
| Human Growth Hormone | 2 | 2017 | 50 | 0.650 |
Why?
| Stress, Physiological | 4 | 2019 | 170 | 0.650 |
Why?
| Nutritional Status | 6 | 2021 | 141 | 0.650 |
Why?
| DNA | 4 | 2007 | 541 | 0.640 |
Why?
| Regional Blood Flow | 10 | 2015 | 108 | 0.630 |
Why?
| Sepsis | 6 | 2019 | 220 | 0.630 |
Why?
| Muscle Cells | 4 | 2009 | 22 | 0.630 |
Why?
| Beverages | 4 | 2019 | 68 | 0.630 |
Why?
| Adrenergic beta-Antagonists | 5 | 2006 | 102 | 0.630 |
Why?
| Diabetes Mellitus | 2 | 2020 | 285 | 0.610 |
Why?
| Critical Care | 2 | 2017 | 213 | 0.600 |
Why?
| Lipids | 7 | 2022 | 147 | 0.600 |
Why?
| Glucose Intolerance | 4 | 2020 | 27 | 0.590 |
Why?
| Cardiovascular Diseases | 4 | 2021 | 440 | 0.590 |
Why?
| Hypolipidemic Agents | 2 | 2007 | 27 | 0.580 |
Why?
| Fenofibrate | 2 | 2007 | 17 | 0.580 |
Why?
| Time Factors | 19 | 2021 | 2903 | 0.580 |
Why?
| Chromatography, High Pressure Liquid | 4 | 2007 | 349 | 0.580 |
Why?
| Eating | 9 | 2024 | 162 | 0.570 |
Why?
| Skin Transplantation | 3 | 2007 | 43 | 0.570 |
Why?
| Young Adult | 15 | 2021 | 3958 | 0.560 |
Why?
| Spectrometry, Mass, Electrospray Ionization | 3 | 2005 | 62 | 0.550 |
Why?
| Kidney Failure, Chronic | 7 | 2015 | 198 | 0.550 |
Why?
| Fatty Acids | 6 | 2013 | 146 | 0.540 |
Why?
| Weight Lifting | 3 | 2004 | 29 | 0.530 |
Why?
| Homeostasis | 3 | 2014 | 200 | 0.530 |
Why?
| Proteolysis | 5 | 2020 | 94 | 0.530 |
Why?
| Cardiovascular Agents | 1 | 2015 | 54 | 0.510 |
Why?
| Citrulline | 1 | 2015 | 95 | 0.500 |
Why?
| Diet, Reducing | 1 | 2015 | 36 | 0.500 |
Why?
| Epidermis | 2 | 2006 | 27 | 0.490 |
Why?
| Metabolomics | 1 | 2016 | 126 | 0.490 |
Why?
| Nutritional Support | 1 | 2014 | 34 | 0.490 |
Why?
| Zinc | 2 | 2022 | 53 | 0.480 |
Why?
| Testosterone | 5 | 2007 | 139 | 0.480 |
Why?
| Ileum | 3 | 2019 | 89 | 0.480 |
Why?
| Adipose Tissue | 4 | 2013 | 187 | 0.480 |
Why?
| Gas Chromatography-Mass Spectrometry | 4 | 2016 | 67 | 0.470 |
Why?
| Protein Stability | 2 | 2017 | 43 | 0.470 |
Why?
| Administration, Oral | 9 | 2009 | 426 | 0.460 |
Why?
| Up-Regulation | 1 | 2015 | 452 | 0.460 |
Why?
| Radiopharmaceuticals | 1 | 2014 | 209 | 0.450 |
Why?
| Nitrogen Isotopes | 7 | 2022 | 36 | 0.450 |
Why?
| Muscle Development | 1 | 2013 | 24 | 0.440 |
Why?
| Biological Availability | 4 | 2019 | 122 | 0.440 |
Why?
| PPAR alpha | 3 | 2007 | 58 | 0.440 |
Why?
| Adolescent | 23 | 2024 | 6356 | 0.430 |
Why?
| Infusions, Intravenous | 9 | 2021 | 206 | 0.430 |
Why?
| Body Mass Index | 13 | 2022 | 652 | 0.430 |
Why?
| Frail Elderly | 1 | 2012 | 32 | 0.420 |
Why?
| Activities of Daily Living | 2 | 2014 | 174 | 0.420 |
Why?
| Palmitoyl Coenzyme A | 4 | 2015 | 4 | 0.420 |
Why?
| Biopsy | 9 | 2011 | 584 | 0.420 |
Why?
| Glutamine | 2 | 2003 | 171 | 0.400 |
Why?
| Glycerol | 4 | 2009 | 15 | 0.400 |
Why?
| Fibroblasts | 2 | 2004 | 345 | 0.400 |
Why?
| Mitochondria | 4 | 2024 | 402 | 0.400 |
Why?
| Nutritional Physiological Phenomena | 4 | 2018 | 22 | 0.390 |
Why?
| Hormones | 5 | 2019 | 55 | 0.390 |
Why?
| Extracellular Fluid | 3 | 2006 | 15 | 0.380 |
Why?
| Phospholipids | 2 | 2020 | 57 | 0.380 |
Why?
| Threonine | 3 | 2022 | 16 | 0.380 |
Why?
| Metabolism | 5 | 2020 | 25 | 0.370 |
Why?
| Heart Rate | 3 | 2007 | 293 | 0.370 |
Why?
| Arthroplasty, Replacement, Hip | 2 | 2021 | 261 | 0.370 |
Why?
| Physical Endurance | 3 | 2024 | 30 | 0.370 |
Why?
| Hospitalization | 3 | 2012 | 652 | 0.370 |
Why?
| Nitrogen | 5 | 2022 | 66 | 0.360 |
Why?
| Immobilization | 2 | 2007 | 14 | 0.360 |
Why?
| Cytokines | 4 | 2007 | 612 | 0.350 |
Why?
| Nutritive Value | 3 | 2017 | 37 | 0.340 |
Why?
| Muscular Diseases | 3 | 2006 | 58 | 0.340 |
Why?
| Cardiac Output | 2 | 2006 | 34 | 0.340 |
Why?
| Oxidation-Reduction | 7 | 2020 | 322 | 0.340 |
Why?
| Biological Transport | 8 | 2013 | 174 | 0.330 |
Why?
| Propanolamines | 2 | 2006 | 14 | 0.330 |
Why?
| Lung Compliance | 2 | 2006 | 8 | 0.330 |
Why?
| Urea | 4 | 2022 | 77 | 0.330 |
Why?
| Hypertriglyceridemia | 1 | 2008 | 13 | 0.330 |
Why?
| Musculoskeletal Physiological Phenomena | 2 | 2013 | 7 | 0.320 |
Why?
| Models, Animal | 4 | 2016 | 233 | 0.320 |
Why?
| Propranolol | 3 | 2006 | 78 | 0.320 |
Why?
| Area Under Curve | 6 | 2008 | 182 | 0.320 |
Why?
| Blood Flow Velocity | 6 | 2007 | 101 | 0.320 |
Why?
| Diet, Carbohydrate-Restricted | 2 | 2018 | 11 | 0.320 |
Why?
| Fibrinogen | 2 | 2005 | 31 | 0.320 |
Why?
| Case-Control Studies | 7 | 2010 | 1131 | 0.310 |
Why?
| Diet, Protein-Restricted | 3 | 2024 | 8 | 0.310 |
Why?
| Hemoglobins | 2 | 2006 | 107 | 0.310 |
Why?
| Protein Kinase C | 1 | 2008 | 71 | 0.310 |
Why?
| Reproducibility of Results | 6 | 2016 | 1193 | 0.310 |
Why?
| Soft Tissue Injuries | 1 | 2008 | 17 | 0.310 |
Why?
| RNA, Transfer, Amino Acyl | 1 | 2007 | 1 | 0.310 |
Why?
| Intracellular Fluid | 2 | 2005 | 12 | 0.310 |
Why?
| Protein Processing, Post-Translational | 1 | 2009 | 171 | 0.310 |
Why?
| Treatment Outcome | 15 | 2020 | 5141 | 0.300 |
Why?
| Absorptiometry, Photon | 5 | 2020 | 154 | 0.300 |
Why?
| Alanine | 3 | 2004 | 42 | 0.300 |
Why?
| Acetates | 1 | 2007 | 49 | 0.290 |
Why?
| Child | 19 | 2022 | 6847 | 0.290 |
Why?
| Insulin, Long-Acting | 1 | 2007 | 1 | 0.290 |
Why?
| Herpesvirus 4, Human | 1 | 2007 | 35 | 0.290 |
Why?
| Intermittent Claudication | 1 | 2007 | 12 | 0.290 |
Why?
| Pseudomonas Infections | 2 | 2017 | 48 | 0.290 |
Why?
| Virus Activation | 1 | 2007 | 32 | 0.290 |
Why?
| Carbon Dioxide | 1 | 2007 | 91 | 0.290 |
Why?
| Peripheral Vascular Diseases | 1 | 2007 | 21 | 0.290 |
Why?
| Acyl Coenzyme A | 2 | 2006 | 8 | 0.280 |
Why?
| Body Weight | 6 | 2013 | 513 | 0.280 |
Why?
| Muscles | 2 | 2006 | 103 | 0.280 |
Why?
| Dose-Response Relationship, Drug | 6 | 2009 | 1376 | 0.280 |
Why?
| Creatine | 2 | 2016 | 37 | 0.280 |
Why?
| Carnitine | 2 | 2010 | 62 | 0.280 |
Why?
| Hemodynamics | 2 | 2017 | 228 | 0.280 |
Why?
| Malnutrition | 3 | 2021 | 87 | 0.280 |
Why?
| Dermis | 2 | 2004 | 18 | 0.280 |
Why?
| Mafenide | 1 | 2006 | 1 | 0.280 |
Why?
| Adrenergic beta-1 Receptor Antagonists | 1 | 2006 | 6 | 0.270 |
Why?
| Living Donors | 1 | 2006 | 23 | 0.270 |
Why?
| Valine | 2 | 2003 | 58 | 0.270 |
Why?
| Military Personnel | 2 | 2019 | 159 | 0.270 |
Why?
| Models, Theoretical | 3 | 2016 | 175 | 0.260 |
Why?
| Hormone Replacement Therapy | 1 | 2005 | 27 | 0.260 |
Why?
| Mitochondrial Proteins | 3 | 2022 | 90 | 0.260 |
Why?
| Fatty Liver | 2 | 2024 | 127 | 0.260 |
Why?
| Shock, Hemorrhagic | 1 | 2005 | 11 | 0.260 |
Why?
| Brain Injuries | 1 | 2007 | 160 | 0.250 |
Why?
| Mitochondrial Dynamics | 3 | 2024 | 18 | 0.250 |
Why?
| Walkers | 1 | 2004 | 2 | 0.250 |
Why?
| Blood Coagulation | 1 | 2005 | 56 | 0.250 |
Why?
| Physical Conditioning, Animal | 2 | 2024 | 52 | 0.240 |
Why?
| PPAR delta | 1 | 2024 | 2 | 0.240 |
Why?
| Dynamins | 1 | 2024 | 7 | 0.240 |
Why?
| Glucose Clamp Technique | 5 | 2009 | 15 | 0.240 |
Why?
| Malonyl Coenzyme A | 2 | 2010 | 7 | 0.240 |
Why?
| Caseins | 1 | 2004 | 80 | 0.240 |
Why?
| Exercise Tolerance | 1 | 2004 | 36 | 0.240 |
Why?
| Hyperandrogenism | 1 | 2024 | 1 | 0.240 |
Why?
| Physical Exertion | 1 | 2004 | 44 | 0.240 |
Why?
| Polycystic Ovary Syndrome | 1 | 2024 | 12 | 0.240 |
Why?
| Child, Preschool | 10 | 2022 | 3871 | 0.230 |
Why?
| Metabolic Clearance Rate | 5 | 2019 | 68 | 0.230 |
Why?
| Developed Countries | 1 | 2024 | 11 | 0.230 |
Why?
| Dietary Fats | 2 | 2017 | 133 | 0.230 |
Why?
| Egg Proteins | 2 | 2021 | 18 | 0.230 |
Why?
| Inulin | 1 | 2003 | 7 | 0.230 |
Why?
| Cell Division | 4 | 2006 | 292 | 0.230 |
Why?
| Disabled Persons | 1 | 2004 | 78 | 0.230 |
Why?
| Disease Models, Animal | 3 | 2019 | 1455 | 0.230 |
Why?
| Meat | 3 | 2021 | 55 | 0.230 |
Why?
| Algorithms | 5 | 2015 | 615 | 0.230 |
Why?
| Injections, Intravenous | 2 | 2014 | 140 | 0.230 |
Why?
| Glycine | 4 | 2004 | 75 | 0.220 |
Why?
| Accidental Falls | 1 | 2004 | 98 | 0.220 |
Why?
| Nutrition Surveys | 1 | 2024 | 104 | 0.220 |
Why?
| Eukaryotic Initiation Factor-2B | 1 | 2003 | 5 | 0.220 |
Why?
| Carnitine O-Palmitoyltransferase | 1 | 2002 | 7 | 0.220 |
Why?
| Pseudomonas aeruginosa | 3 | 2019 | 72 | 0.220 |
Why?
| Reference Values | 6 | 2017 | 310 | 0.220 |
Why?
| Carbohydrate Metabolism | 2 | 2019 | 26 | 0.220 |
Why?
| Weightlessness | 1 | 2002 | 14 | 0.210 |
Why?
| Tyrosine | 4 | 2022 | 95 | 0.210 |
Why?
| Vasodilator Agents | 1 | 2003 | 96 | 0.210 |
Why?
| Splanchnic Circulation | 1 | 2002 | 40 | 0.210 |
Why?
| Polymers | 1 | 2022 | 40 | 0.210 |
Why?
| Space Flight | 1 | 2002 | 34 | 0.210 |
Why?
| Pulmonary Surfactants | 1 | 2002 | 18 | 0.210 |
Why?
| Alaska | 2 | 2020 | 22 | 0.210 |
Why?
| GTP-Binding Proteins | 1 | 2022 | 90 | 0.210 |
Why?
| Diet, High-Fat | 2 | 2024 | 222 | 0.210 |
Why?
| Reindeer | 1 | 2021 | 3 | 0.200 |
Why?
| Calorimetry, Indirect | 4 | 2006 | 25 | 0.200 |
Why?
| Autophagy | 2 | 2020 | 169 | 0.200 |
Why?
| Age Factors | 6 | 2017 | 1087 | 0.200 |
Why?
| Injections, Intramuscular | 3 | 2011 | 54 | 0.200 |
Why?
| Mice, Knockout | 1 | 2024 | 841 | 0.200 |
Why?
| Myostatin | 1 | 2021 | 8 | 0.190 |
Why?
| Fasting | 4 | 2020 | 70 | 0.190 |
Why?
| Neoplasms | 1 | 2011 | 1235 | 0.190 |
Why?
| Proteolipids | 1 | 2021 | 10 | 0.190 |
Why?
| Leptin | 1 | 2022 | 140 | 0.190 |
Why?
| Lysine | 2 | 2017 | 89 | 0.190 |
Why?
| Severity of Illness Index | 4 | 2017 | 945 | 0.190 |
Why?
| Glycogenolysis | 1 | 2020 | 10 | 0.190 |
Why?
| Plant Proteins | 1 | 2021 | 70 | 0.190 |
Why?
| Health Status | 2 | 2016 | 298 | 0.190 |
Why?
| Prospective Studies | 5 | 2017 | 2364 | 0.190 |
Why?
| Palmitic Acid | 4 | 2005 | 22 | 0.180 |
Why?
| Random Allocation | 2 | 2015 | 281 | 0.180 |
Why?
| Femoral Artery | 3 | 2007 | 100 | 0.180 |
Why?
| Hyperphagia | 1 | 2020 | 10 | 0.180 |
Why?
| Postoperative Care | 1 | 2021 | 102 | 0.180 |
Why?
| Hypoglycemia | 1 | 2020 | 51 | 0.180 |
Why?
| Fatty Acids, Omega-3 | 1 | 2020 | 28 | 0.180 |
Why?
| Analysis of Variance | 6 | 2009 | 562 | 0.180 |
Why?
| Breast Feeding | 1 | 2022 | 187 | 0.180 |
Why?
| Fatty Liver, Alcoholic | 1 | 2020 | 7 | 0.180 |
Why?
| Enteral Nutrition | 4 | 2006 | 147 | 0.180 |
Why?
| RNA, Messenger | 2 | 2022 | 1105 | 0.180 |
Why?
| Preoperative Care | 1 | 2021 | 164 | 0.180 |
Why?
| Health | 2 | 2012 | 25 | 0.170 |
Why?
| Carcinoma, Hepatocellular | 1 | 2022 | 191 | 0.170 |
Why?
| United States | 5 | 2024 | 4860 | 0.170 |
Why?
| Mouth | 1 | 2019 | 33 | 0.170 |
Why?
| Fruit | 1 | 2020 | 136 | 0.170 |
Why?
| Hindlimb | 3 | 2008 | 30 | 0.170 |
Why?
| Molecular Probe Techniques | 1 | 2019 | 9 | 0.170 |
Why?
| Water | 1 | 2019 | 77 | 0.170 |
Why?
| Radioisotope Dilution Technique | 3 | 2004 | 12 | 0.170 |
Why?
| Military Medicine | 1 | 2019 | 22 | 0.170 |
Why?
| Palmitoylcarnitine | 2 | 2011 | 6 | 0.170 |
Why?
| Evaluation Studies as Topic | 1 | 2019 | 107 | 0.170 |
Why?
| Altitude Sickness | 2 | 2012 | 7 | 0.170 |
Why?
| Intestinal Absorption | 1 | 2019 | 57 | 0.160 |
Why?
| Proteome | 1 | 2020 | 173 | 0.160 |
Why?
| Jejunum | 1 | 2019 | 54 | 0.160 |
Why?
| Hypoalbuminemia | 1 | 2018 | 4 | 0.160 |
Why?
| Basal Metabolism | 3 | 2020 | 31 | 0.160 |
Why?
| Lung | 1 | 2002 | 486 | 0.160 |
Why?
| Occupational Diseases | 1 | 2019 | 89 | 0.160 |
Why?
| Liver Neoplasms | 1 | 2022 | 326 | 0.160 |
Why?
| Cholesterol | 3 | 2013 | 146 | 0.150 |
Why?
| Inflammation | 4 | 2018 | 604 | 0.150 |
Why?
| Alcohol Drinking | 1 | 2020 | 224 | 0.150 |
Why?
| Oxandrolone | 2 | 2011 | 10 | 0.150 |
Why?
| Lower Extremity | 2 | 2009 | 88 | 0.150 |
Why?
| Breakfast | 1 | 2017 | 15 | 0.150 |
Why?
| Gastrointestinal Tract | 1 | 2018 | 103 | 0.150 |
Why?
| Intestinal Mucosa | 1 | 2019 | 225 | 0.150 |
Why?
| Oxygen Consumption | 6 | 2019 | 183 | 0.150 |
Why?
| Injections, Intradermal | 2 | 2007 | 14 | 0.150 |
Why?
| Circadian Rhythm | 1 | 2017 | 88 | 0.150 |
Why?
| Hypertension, Pulmonary | 2 | 2012 | 114 | 0.140 |
Why?
| Quadriceps Muscle | 1 | 2017 | 46 | 0.140 |
Why?
| Nutrition Assessment | 1 | 2017 | 63 | 0.140 |
Why?
| Sleep Apnea, Obstructive | 1 | 2017 | 67 | 0.140 |
Why?
| Athletic Performance | 1 | 2016 | 29 | 0.140 |
Why?
| Endpoint Determination | 1 | 2016 | 24 | 0.140 |
Why?
| Egg Proteins, Dietary | 1 | 2016 | 2 | 0.140 |
Why?
| Food Quality | 1 | 2016 | 2 | 0.140 |
Why?
| Physical Fitness | 2 | 2014 | 54 | 0.140 |
Why?
| Mice | 6 | 2024 | 5739 | 0.140 |
Why?
| Chromatography, Liquid | 2 | 2008 | 232 | 0.140 |
Why?
| Rest | 2 | 2007 | 63 | 0.130 |
Why?
| Tissue Donors | 2 | 2007 | 111 | 0.130 |
Why?
| Hyperemia | 1 | 2015 | 19 | 0.130 |
Why?
| Chronic Disease | 4 | 2017 | 567 | 0.130 |
Why?
| Forearm | 1 | 2015 | 31 | 0.130 |
Why?
| Magnetic Resonance Spectroscopy | 2 | 2008 | 244 | 0.130 |
Why?
| Constriction | 2 | 2007 | 9 | 0.130 |
Why?
| Capillaries | 2 | 2007 | 50 | 0.130 |
Why?
| Microdialysis | 2 | 2005 | 18 | 0.130 |
Why?
| Waist Circumference | 1 | 2015 | 19 | 0.130 |
Why?
| Hand Strength | 1 | 2015 | 23 | 0.130 |
Why?
| Cross-Sectional Studies | 3 | 2008 | 1557 | 0.120 |
Why?
| Femoral Vein | 2 | 2005 | 40 | 0.120 |
Why?
| Radioactive Tracers | 2 | 2019 | 8 | 0.120 |
Why?
| NF-kappa B | 2 | 2007 | 314 | 0.120 |
Why?
| Logistic Models | 2 | 2015 | 888 | 0.120 |
Why?
| Proline | 2 | 2004 | 30 | 0.120 |
Why?
| Endothelium, Vascular | 1 | 2015 | 252 | 0.120 |
Why?
| Exercise Test | 3 | 2019 | 121 | 0.110 |
Why?
| Weight Gain | 2 | 2022 | 240 | 0.110 |
Why?
| Statistics, Nonparametric | 2 | 2011 | 194 | 0.110 |
Why?
| Pulmonary Edema | 2 | 2004 | 18 | 0.110 |
Why?
| Motor Activity | 3 | 2010 | 229 | 0.110 |
Why?
| Walking | 1 | 2014 | 94 | 0.110 |
Why?
| Carbohydrates | 2 | 2019 | 40 | 0.110 |
Why?
| Evidence-Based Medicine | 2 | 2012 | 247 | 0.110 |
Why?
| Risk Assessment | 4 | 2017 | 1259 | 0.110 |
Why?
| Extremities | 1 | 2013 | 30 | 0.110 |
Why?
| Tissue and Organ Procurement | 2 | 2004 | 39 | 0.110 |
Why?
| Oxygen | 2 | 2006 | 326 | 0.110 |
Why?
| Arginase | 1 | 2012 | 35 | 0.100 |
Why?
| Follow-Up Studies | 4 | 2017 | 2182 | 0.100 |
Why?
| Cystic Fibrosis | 2 | 2013 | 147 | 0.100 |
Why?
| Altitude | 1 | 2012 | 16 | 0.100 |
Why?
| Metabolic Diseases | 1 | 2012 | 40 | 0.100 |
Why?
| Nitric Oxide Synthase | 2 | 2012 | 75 | 0.100 |
Why?
| Guidelines as Topic | 1 | 2012 | 111 | 0.100 |
Why?
| Organ Size | 1 | 2012 | 226 | 0.100 |
Why?
| Healthcare Disparities | 1 | 2015 | 257 | 0.100 |
Why?
| Cattle | 2 | 2022 | 210 | 0.100 |
Why?
| Glucose Tolerance Test | 3 | 2010 | 57 | 0.100 |
Why?
| Liver Transplantation | 2 | 2004 | 148 | 0.100 |
Why?
| Cell Line | 2 | 2004 | 1000 | 0.100 |
Why?
| Pulmonary Artery | 1 | 2012 | 145 | 0.090 |
Why?
| Parenteral Nutrition | 2 | 2016 | 27 | 0.090 |
Why?
| Breath Tests | 2 | 2007 | 39 | 0.090 |
Why?
| Cushing Syndrome | 1 | 2009 | 10 | 0.090 |
Why?
| Randomized Controlled Trials as Topic | 3 | 2022 | 549 | 0.090 |
Why?
| Texas | 2 | 2007 | 137 | 0.090 |
Why?
| Blood Pressure | 2 | 2017 | 512 | 0.080 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 142 | 0.080 |
Why?
| Insulin-Like Growth Factor I | 2 | 2007 | 137 | 0.080 |
Why?
| Antiphospholipid Syndrome | 1 | 2009 | 9 | 0.080 |
Why?
| Cholesterol, VLDL | 1 | 2008 | 3 | 0.080 |
Why?
| Polysomnography | 2 | 2020 | 71 | 0.080 |
Why?
| Body Surface Area | 2 | 2006 | 24 | 0.080 |
Why?
| Institutionalization | 1 | 2008 | 12 | 0.080 |
Why?
| Cachexia | 1 | 2008 | 25 | 0.080 |
Why?
| Satiation | 1 | 2008 | 8 | 0.080 |
Why?
| Kidney Function Tests | 1 | 2008 | 49 | 0.080 |
Why?
| Muscle Strength Dynamometer | 1 | 2008 | 12 | 0.080 |
Why?
| Fontan Procedure | 1 | 2009 | 64 | 0.080 |
Why?
| Gene Expression Regulation | 4 | 2010 | 976 | 0.080 |
Why?
| Linear Models | 2 | 2009 | 280 | 0.080 |
Why?
| Parenteral Nutrition Solutions | 2 | 2004 | 8 | 0.080 |
Why?
| Citric Acid Cycle | 1 | 2007 | 16 | 0.080 |
Why?
| Solutions | 2 | 2004 | 25 | 0.080 |
Why?
| RNA, Transfer | 1 | 2007 | 16 | 0.080 |
Why?
| Sodium Bicarbonate | 1 | 2007 | 9 | 0.080 |
Why?
| Ketoconazole | 1 | 2007 | 17 | 0.080 |
Why?
| Sleep | 2 | 2020 | 184 | 0.080 |
Why?
| Electrolytes | 2 | 2004 | 26 | 0.070 |
Why?
| Space Simulation | 1 | 2007 | 2 | 0.070 |
Why?
| Placebos | 2 | 2004 | 85 | 0.070 |
Why?
| Hypoplastic Left Heart Syndrome | 1 | 2009 | 96 | 0.070 |
Why?
| Mice, Inbred C57BL | 2 | 2024 | 1816 | 0.070 |
Why?
| Gait | 1 | 2008 | 85 | 0.070 |
Why?
| Tandem Mass Spectrometry | 1 | 2008 | 236 | 0.070 |
Why?
| Adenosine Triphosphate | 1 | 2008 | 233 | 0.070 |
Why?
| Virus Latency | 1 | 2007 | 47 | 0.070 |
Why?
| Saliva | 1 | 2007 | 54 | 0.070 |
Why?
| Acute Disease | 2 | 2019 | 366 | 0.070 |
Why?
| Trauma Severity Indices | 1 | 2007 | 47 | 0.070 |
Why?
| Sex Factors | 2 | 2020 | 691 | 0.070 |
Why?
| Cell Compartmentation | 1 | 2006 | 10 | 0.070 |
Why?
| Waiting Lists | 2 | 2004 | 49 | 0.070 |
Why?
| RNA | 1 | 2007 | 170 | 0.070 |
Why?
| Risk Factors | 4 | 2019 | 3613 | 0.070 |
Why?
| Siloxanes | 1 | 2006 | 2 | 0.070 |
Why?
| Styrenes | 1 | 2006 | 2 | 0.070 |
Why?
| Occlusive Dressings | 1 | 2006 | 6 | 0.070 |
Why?
| Osmolar Concentration | 2 | 2003 | 62 | 0.070 |
Why?
| APACHE | 1 | 2006 | 23 | 0.070 |
Why?
| Administration, Topical | 1 | 2006 | 56 | 0.070 |
Why?
| Dermatologic Surgical Procedures | 1 | 2006 | 34 | 0.070 |
Why?
| Bandages | 1 | 2006 | 25 | 0.070 |
Why?
| Hepatomegaly | 1 | 2006 | 7 | 0.070 |
Why?
| Resource Allocation | 2 | 2004 | 16 | 0.070 |
Why?
| Anti-Infective Agents, Local | 1 | 2006 | 25 | 0.070 |
Why?
| Methods | 1 | 2005 | 55 | 0.070 |
Why?
| Carbohydrate Sequence | 1 | 2005 | 11 | 0.070 |
Why?
| Creatinine | 1 | 2006 | 139 | 0.070 |
Why?
| Injury Severity Score | 1 | 2006 | 159 | 0.070 |
Why?
| Anti-Inflammatory Agents | 1 | 2007 | 161 | 0.070 |
Why?
| Reference Standards | 1 | 2005 | 56 | 0.070 |
Why?
| Infusions, Intra-Arterial | 1 | 2005 | 15 | 0.070 |
Why?
| Pressure Ulcer | 1 | 2005 | 15 | 0.060 |
Why?
| Fibrinolysis | 1 | 2005 | 5 | 0.060 |
Why?
| Body Water | 1 | 2005 | 23 | 0.060 |
Why?
| Life Style | 1 | 2006 | 140 | 0.060 |
Why?
| Blood Coagulation Tests | 1 | 2005 | 19 | 0.060 |
Why?
| Hematocrit | 1 | 2005 | 44 | 0.060 |
Why?
| Milk | 1 | 2006 | 85 | 0.060 |
Why?
| Fluorocarbons | 1 | 2005 | 45 | 0.060 |
Why?
| Arteries | 2 | 2004 | 93 | 0.060 |
Why?
| Stress, Psychological | 1 | 2007 | 260 | 0.060 |
Why?
| Practice Guidelines as Topic | 1 | 2008 | 449 | 0.060 |
Why?
| Ecchymosis | 1 | 2004 | 8 | 0.060 |
Why?
| Osteoporosis | 1 | 2006 | 146 | 0.060 |
Why?
| Myocardial Infarction | 1 | 2009 | 389 | 0.060 |
Why?
| Blood Specimen Collection | 1 | 2004 | 34 | 0.060 |
Why?
| Signal Transduction | 3 | 2020 | 1618 | 0.060 |
Why?
| Biological Transport, Active | 1 | 2004 | 30 | 0.060 |
Why?
| Muscle Fatigue | 1 | 2004 | 10 | 0.060 |
Why?
| Amino Acid Sequence | 1 | 2005 | 585 | 0.060 |
Why?
| Hematoma | 1 | 2004 | 64 | 0.060 |
Why?
| Culture Media | 1 | 2004 | 94 | 0.060 |
Why?
| Catheterization | 1 | 2004 | 96 | 0.060 |
Why?
| Biopsy, Needle | 1 | 2004 | 183 | 0.060 |
Why?
| Locomotion | 1 | 2004 | 92 | 0.060 |
Why?
| Molecular Sequence Data | 1 | 2005 | 792 | 0.060 |
Why?
| Health Care Rationing | 1 | 2004 | 11 | 0.060 |
Why?
| Interleukin-18 | 1 | 2024 | 27 | 0.060 |
Why?
| Respiratory Function Tests | 1 | 2004 | 90 | 0.060 |
Why?
| Iontophoresis | 1 | 2003 | 14 | 0.060 |
Why?
| Albumins | 1 | 2004 | 31 | 0.060 |
Why?
| Physical Education and Training | 1 | 2004 | 24 | 0.060 |
Why?
| Pilocarpine | 1 | 2003 | 25 | 0.060 |
Why?
| Amino Acid Transport Systems | 1 | 2003 | 5 | 0.060 |
Why?
| Adaptation, Physiological | 1 | 2004 | 91 | 0.060 |
Why?
| Equipment Design | 1 | 2004 | 284 | 0.060 |
Why?
| RNA, Ribosomal, 16S | 1 | 2024 | 113 | 0.060 |
Why?
| Glutamic Acid | 1 | 2004 | 107 | 0.060 |
Why?
| Cell Count | 1 | 2004 | 147 | 0.060 |
Why?
| Injections, Intra-Arterial | 1 | 2003 | 13 | 0.060 |
Why?
| Nitric Oxide Donors | 1 | 2003 | 10 | 0.060 |
Why?
| Nitroprusside | 1 | 2003 | 10 | 0.060 |
Why?
| Cough | 1 | 2003 | 54 | 0.060 |
Why?
| Obesity, Morbid | 1 | 2004 | 78 | 0.060 |
Why?
| Regression Analysis | 1 | 2004 | 395 | 0.060 |
Why?
| Computer Simulation | 1 | 2004 | 280 | 0.060 |
Why?
| Time | 1 | 2003 | 25 | 0.060 |
Why?
| Ovarian Neoplasms | 1 | 2007 | 447 | 0.060 |
Why?
| Blood Circulation | 1 | 2003 | 15 | 0.050 |
Why?
| Coloring Agents | 1 | 2003 | 69 | 0.050 |
Why?
| Carbazoles | 1 | 2003 | 16 | 0.050 |
Why?
| Ventricular Dysfunction | 1 | 2003 | 9 | 0.050 |
Why?
| Hydroxyproline | 1 | 2003 | 19 | 0.050 |
Why?
| Indocyanine Green | 1 | 2003 | 34 | 0.050 |
Why?
| Body Constitution | 1 | 2002 | 12 | 0.050 |
Why?
| Weightlessness Countermeasures | 1 | 2002 | 2 | 0.050 |
Why?
| Transposition of Great Vessels | 1 | 2003 | 25 | 0.050 |
Why?
| Drug Combinations | 1 | 2003 | 123 | 0.050 |
Why?
| Cell Membrane | 1 | 2003 | 248 | 0.050 |
Why?
| Kidney Diseases | 1 | 2005 | 214 | 0.050 |
Why?
| Blood Proteins | 1 | 2023 | 82 | 0.050 |
Why?
| Fish Oils | 1 | 2002 | 12 | 0.050 |
Why?
| Linoleic Acid | 1 | 2002 | 14 | 0.050 |
Why?
| Phosphatidylcholines | 1 | 2002 | 25 | 0.050 |
Why?
| Fat Emulsions, Intravenous | 1 | 2002 | 11 | 0.050 |
Why?
| Ear | 1 | 2002 | 17 | 0.050 |
Why?
| Microspheres | 1 | 2002 | 25 | 0.050 |
Why?
| Leukocyte Count | 1 | 2002 | 70 | 0.050 |
Why?
| Endotoxins | 1 | 2002 | 34 | 0.050 |
Why?
| Lactates | 1 | 2022 | 29 | 0.050 |
Why?
| Communicable Disease Control | 1 | 2022 | 39 | 0.050 |
Why?
| Ribosomal Proteins | 1 | 2022 | 25 | 0.050 |
Why?
| Carotid Arteries | 1 | 2002 | 85 | 0.050 |
Why?
| Drug Synergism | 1 | 2002 | 150 | 0.050 |
Why?
| Sensitivity and Specificity | 1 | 2004 | 861 | 0.050 |
Why?
| Thinness | 2 | 2016 | 46 | 0.050 |
Why?
| Neutrophils | 1 | 2002 | 145 | 0.050 |
Why?
| Cell Cycle Proteins | 1 | 2022 | 166 | 0.050 |
Why?
| Gene Expression | 1 | 2003 | 609 | 0.050 |
Why?
| Orthopedic Procedures | 1 | 2021 | 68 | 0.050 |
Why?
| Food | 1 | 2020 | 72 | 0.050 |
Why?
| Ceramides | 1 | 2020 | 28 | 0.050 |
Why?
| Tumor Microenvironment | 1 | 2022 | 212 | 0.050 |
Why?
| Dexamethasone | 1 | 2022 | 430 | 0.040 |
Why?
| Protein Kinases | 1 | 2020 | 71 | 0.040 |
Why?
| T-Lymphocytes | 1 | 2022 | 338 | 0.040 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2020 | 157 | 0.040 |
Why?
| Occupational Health | 1 | 2019 | 68 | 0.040 |
Why?
| Capillary Permeability | 1 | 2018 | 35 | 0.040 |
Why?
| Rats, Zucker | 2 | 2010 | 69 | 0.040 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2004 | 477 | 0.040 |
Why?
| Apoptosis | 1 | 2003 | 1101 | 0.040 |
Why?
| Body Weights and Measures | 1 | 2017 | 17 | 0.040 |
Why?
| Artifacts | 1 | 2018 | 53 | 0.040 |
Why?
| Hunger | 1 | 2017 | 15 | 0.040 |
Why?
| Animal Structures | 1 | 2017 | 2 | 0.040 |
Why?
| Clinical Chemistry Tests | 1 | 2017 | 2 | 0.040 |
Why?
| Withholding Treatment | 1 | 2017 | 19 | 0.040 |
Why?
| Blood Gas Analysis | 1 | 2017 | 30 | 0.040 |
Why?
| Pilot Projects | 1 | 2020 | 699 | 0.040 |
Why?
| Pandemics | 1 | 2022 | 559 | 0.040 |
Why?
| Indicator Dilution Techniques | 1 | 2017 | 11 | 0.040 |
Why?
| Venae Cavae | 1 | 2017 | 9 | 0.040 |
Why?
| Crosses, Genetic | 1 | 2017 | 31 | 0.040 |
Why?
| Sus scrofa | 1 | 2017 | 36 | 0.040 |
Why?
| Inflammation Mediators | 1 | 2017 | 112 | 0.040 |
Why?
| Continuous Positive Airway Pressure | 1 | 2017 | 56 | 0.040 |
Why?
| Glycogen | 2 | 2010 | 41 | 0.040 |
Why?
| Caffeine | 1 | 2016 | 67 | 0.030 |
Why?
| Catheterization, Central Venous | 1 | 2017 | 86 | 0.030 |
Why?
| Oxidative Stress | 1 | 2020 | 770 | 0.030 |
Why?
| Research Design | 1 | 2017 | 344 | 0.030 |
Why?
| Gastrointestinal Diseases | 1 | 2016 | 126 | 0.030 |
Why?
| Multienzyme Complexes | 2 | 2006 | 34 | 0.030 |
Why?
| Cardiac Catheterization | 2 | 2009 | 201 | 0.030 |
Why?
| Pregnancy | 1 | 2022 | 2607 | 0.030 |
Why?
| Predictive Value of Tests | 1 | 2017 | 903 | 0.030 |
Why?
| Diagnostic Imaging | 1 | 2016 | 176 | 0.030 |
Why?
| Postoperative Complications | 1 | 2021 | 984 | 0.030 |
Why?
| Proportional Hazards Models | 1 | 2015 | 402 | 0.030 |
Why?
| Octreotide | 1 | 2013 | 9 | 0.030 |
Why?
| Subcutaneous Fat, Abdominal | 1 | 2013 | 6 | 0.030 |
Why?
| Intra-Abdominal Fat | 1 | 2013 | 20 | 0.030 |
Why?
| Quality of Health Care | 1 | 2015 | 186 | 0.030 |
Why?
| Ubiquitin | 2 | 2003 | 45 | 0.030 |
Why?
| Medicare | 1 | 2015 | 246 | 0.030 |
Why?
| Health Status Disparities | 1 | 2015 | 195 | 0.030 |
Why?
| Colorado | 1 | 2012 | 21 | 0.030 |
Why?
| Rats | 2 | 2010 | 3305 | 0.030 |
Why?
| Age of Onset | 1 | 2012 | 108 | 0.030 |
Why?
| Acetyl-CoA Carboxylase | 1 | 2010 | 13 | 0.020 |
Why?
| Endothelial Cells | 1 | 2012 | 269 | 0.020 |
Why?
| Amino-Acid N-Acetyltransferase | 1 | 2010 | 2 | 0.020 |
Why?
| Sciatic Nerve | 1 | 2010 | 24 | 0.020 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 244 | 0.020 |
Why?
| Clinical Protocols | 1 | 2010 | 108 | 0.020 |
Why?
| Retrospective Studies | 2 | 2012 | 6108 | 0.020 |
Why?
| Drug Administration Schedule | 1 | 2010 | 376 | 0.020 |
Why?
| Protein-Energy Malnutrition | 1 | 2009 | 19 | 0.020 |
Why?
| Cardiac Surgical Procedures | 1 | 2012 | 297 | 0.020 |
Why?
| Chest Pain | 1 | 2009 | 53 | 0.020 |
Why?
| Longitudinal Studies | 1 | 2011 | 688 | 0.020 |
Why?
| Down-Regulation | 1 | 2010 | 348 | 0.020 |
Why?
| Movement | 1 | 2008 | 82 | 0.020 |
Why?
| Thermogenesis | 1 | 2008 | 25 | 0.020 |
Why?
| Patient Discharge | 1 | 2010 | 320 | 0.020 |
Why?
| Blood Chemical Analysis | 1 | 2007 | 27 | 0.020 |
Why?
| Diglycerides | 1 | 2006 | 9 | 0.020 |
Why?
| Coronary Angiography | 1 | 2009 | 334 | 0.020 |
Why?
| Lipolysis | 1 | 2006 | 10 | 0.020 |
Why?
| Electrocardiography | 1 | 2009 | 257 | 0.020 |
Why?
| AMP-Activated Protein Kinases | 1 | 2006 | 30 | 0.020 |
Why?
| Aerobiosis | 1 | 2006 | 14 | 0.020 |
Why?
| Mitogen-Activated Protein Kinases | 1 | 2006 | 155 | 0.020 |
Why?
| Anticoagulants | 1 | 2009 | 250 | 0.020 |
Why?
| Cohort Studies | 1 | 2010 | 1422 | 0.020 |
Why?
| Hematinics | 1 | 2005 | 12 | 0.020 |
Why?
| Surgical Procedures, Operative | 1 | 2006 | 63 | 0.020 |
Why?
| Phosphorylation | 1 | 2006 | 535 | 0.020 |
Why?
| Glomerular Filtration Rate | 1 | 2005 | 111 | 0.020 |
Why?
| Erythropoietin | 1 | 2005 | 51 | 0.020 |
Why?
| Drug Utilization | 1 | 2005 | 77 | 0.020 |
Why?
| Mice, Inbred ICR | 1 | 2004 | 22 | 0.020 |
Why?
| Hindlimb Suspension | 1 | 2004 | 37 | 0.010 |
Why?
| Gastric Bypass | 1 | 2004 | 19 | 0.010 |
Why?
| Diaphragm | 1 | 2004 | 29 | 0.010 |
Why?
| 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) | 1 | 2003 | 2 | 0.010 |
Why?
| Veins | 1 | 2004 | 71 | 0.010 |
Why?
| Bronchiectasis | 1 | 2003 | 9 | 0.010 |
Why?
| Forced Expiratory Volume | 1 | 2003 | 44 | 0.010 |
Why?
| Acidosis | 1 | 2003 | 40 | 0.010 |
Why?
| Caspase 3 | 1 | 2003 | 97 | 0.010 |
Why?
| Complement System Proteins | 1 | 2003 | 46 | 0.010 |
Why?
| Immunoglobulin E | 1 | 2003 | 92 | 0.010 |
Why?
| Extracellular Space | 1 | 2003 | 38 | 0.010 |
Why?
| Infant | 1 | 2012 | 3567 | 0.010 |
Why?
| Food Additives | 1 | 2003 | 9 | 0.010 |
Why?
| Organic Chemicals | 1 | 2003 | 13 | 0.010 |
Why?
| Recombinant Proteins | 1 | 2005 | 486 | 0.010 |
Why?
| Protein Array Analysis | 1 | 2003 | 23 | 0.010 |
Why?
| Caspases | 1 | 2003 | 104 | 0.010 |
Why?
| Graft Survival | 1 | 2004 | 150 | 0.010 |
Why?
| Wound Infection | 1 | 2003 | 27 | 0.010 |
Why?
| Cysteine Endopeptidases | 1 | 2003 | 67 | 0.010 |
Why?
| Comorbidity | 1 | 2004 | 615 | 0.010 |
Why?
| Diuresis | 1 | 2002 | 11 | 0.010 |
Why?
| Patient Selection | 1 | 2004 | 253 | 0.010 |
Why?
| Stroke Volume | 1 | 2003 | 116 | 0.010 |
Why?
| Proteasome Endopeptidase Complex | 1 | 2003 | 114 | 0.010 |
Why?
| Recurrence | 1 | 2003 | 652 | 0.010 |
Why?
| Norepinephrine | 1 | 2002 | 107 | 0.010 |
Why?
| Receptors, Androgen | 1 | 2002 | 46 | 0.010 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2003 | 411 | 0.010 |
Why?
| Combined Modality Therapy | 1 | 2003 | 637 | 0.010 |
Why?
| Incidence | 1 | 2004 | 1003 | 0.010 |
Why?
| Health Policy | 1 | 2002 | 153 | 0.010 |
Why?
| Prostate | 1 | 2002 | 117 | 0.010 |
Why?
| Survival Analysis | 1 | 2002 | 653 | 0.010 |
Why?
| Blotting, Western | 1 | 2002 | 601 | 0.010 |
Why?
| Diagnosis, Differential | 1 | 2003 | 1037 | 0.010 |
Why?
| Gene Expression Profiling | 1 | 2003 | 1032 | 0.010 |
Why?
| Tomography, X-Ray Computed | 1 | 2003 | 1159 | 0.010 |
Why?
|
|
Wolfe's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|